The global biosimilars market is estimated to be valued at USD 21.8 billion in 2023 and is expected to exhibit a compound annual growth rate (CAGR) of x% over the forecast period 2023-2030, according to a report published by Coherent Market Insights. Biosimilars are biologic medical products that are highly similar to an already approved biological product. They offer advantages such as reduced cost compared to the reference product, thus making them an attractive option for patients and healthcare providers. The need for biosimilars is associated with rising healthcare costs and the increasing prevalence of chronic diseases, which require cost-effective treatment options.
Market Key Trends:
One key trend in the biosimilars market is the increasing adoption of biosimilars by healthcare providers and patients. This trend is driven by the cost-effectiveness of biosimilars compared to the reference biologic products. Designed to be highly similar to the reference product, biosimilars offer comparable safety and efficacy at a lower cost. As a result, healthcare providers are increasingly using biosimilars in their treatment plans, which helps to reduce healthcare expenditure. Additionally, patients are also opting for biosimilars due to their cost-effectiveness and accessibility. The growing acceptance and adoption of biosimilars are likely to drive market growth over the forecast period.
Key players in the biosimilars market include Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd., Biocon Limited, Amgen, Inc., Dr. Reddy’s Laboratories, and Sanofi S.A. However, this report does not cover any details on the key players in the market.
The Biosimilars market can be segmented based on product type, application, and end-user. Based on product type, the dominant segment in the market is the monoclonal antibodies. Monoclonal antibodies are used in the treatment of various diseases such as cancer, autoimmune disorders, and inflammatory diseases. They offer targeted therapy, reducing the side effects on the body. The increasing prevalence of cancer and the demand for personalized medicine are driving the growth of the monoclonal antibodies segment. Additionally, the expiry of patents for several blockbuster biologics is creating opportunities for biosimilar manufacturers to develop and commercialize biosimilar monoclonal antibodies. Hence, the monoclonal antibodies segment is expected to dominate the biosimilars market during the forecast period.
The Global Biosimilars Market Size is expected to witness high growth, exhibiting a CAGR of 15.9% over the forecast period. This growth can be attributed to factors such as the increasing prevalence of chronic diseases, rising demand for cost-effective treatment options, and the expiration of patents for several biologic drugs. Biosimilars offer a more affordable alternative to biologics, making them a preferred choice for patients and healthcare providers.
In terms of regional analysis, North America is expected to be the fastest-growing and dominating region in the biosimilars market. This can be attributed to the favorable regulatory environment, presence of key market players, and increasing adoption of biosimilars. Europe is also a significant market for biosimilars, driven by the strong presence of regulatory authorities promoting the use of biosimilars and cost-saving measures implemented by healthcare systems.
Key players operating in the biosimilars market include Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd., Biocon Limited, Amgen, Inc., Dr. Reddy’s Laboratories, and Sanofi S.A. These companies are investing in research and development activities, partnerships, and acquisitions to enhance their market presence and expand their biosimilars portfolio. Novartis AG, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd. are among the key players dominating the biosimilars market, leveraging their strong brand recognition and extensive distribution networks.